Early PET response to neoadjuvant chemo predicts increased survival in sarcoma patients

April 2, 2012

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

Prior studies by this multidisciplinary team of physician scientists at the Jonsson Cancer Center had shown that use of FDG PET/computed tomography (CT) could determine pathologic response after the first dose of . The researchers then wondered if the patients showing a significant PET response after the first round of also were surviving longer, said Dr. Fritz Eilber, an associate professor of surgical oncology, director of the Sarcoma Program at UCLA's Jonsson Cancer Center and senior author of the study.

"We did find that patients who experienced an early PET response to treatment had significantly increased survival," Eilber said. "This is vital because patients want to know if the drugs are working and what that says about their ultimate outcome."

The study was published April 1, 2012 in , a peer-reviewed journal of the American Association of Cancer Research.

In this study, 39 patients with soft tissue sarcoma underwent a PET scan to measure their tumor's , or how much was being taken up by the tumor, prior to getting chemotherapy. The patients were given another after the first round of chemotherapy. Those whose tumors demonstrated a 25 percent or more decrease in – a response considered significant - were determined later to have significant increased survival rates compared to those patients who had less than a 25 percent decrease, Eilber said.

"It's an important finding because we can now identify whether patients are getting the right chemotherapy very quickly," Eilber said. "Patients don't want to have to wait until the cancer recurs or they die to find out whether their chemotherapy worked or not."

Going forward, Eilber and his team are working to design new molecular imaging tools that may tell them even more about a patient's cancer beyond the conventional FDG probe.

"Just looking at the size of the tumor is not good enough anymore," Eilber said. "We want to image what's happening within the tumor in real time."

The study was funded by the In vivo Cellular and Molecular Imaging Center at UCLA's Jonsson Comprehensive Cancer Center and the Department of Energy.

"This study suggests that PET allows survival predictions after the initial cycle of neoadjuvant chemotherapy and might therefore potentially serve as an early endpoint biomarker," the study states. "Such information cannot be derived from CT scanning based on serial tumor size measurements. The ability to assess treatment response early during the course of therapy can potentially guide management decisions. Treatment could be switched from neoadjuvant chemotherapy to immediate surgery in non-responding patients, while it would be continued in responders. Such risk adapted therapy could reduce treatment associated morbidity and costs."

Explore further: Quantitative PET imaging finds early determination of effectiveness of cancer treatment

Related Stories

Recommended for you

Oxygen can impair cancer immunotherapy in mice

August 25, 2016

Researchers have identified a mechanism in mice by which anticancer immune responses are inhibited within the lungs, a common site of metastasis for many cancers. This mechanism involves oxygen inhibition of the anticancer ...

Stem cell propagation fuels cancer risk in different organs

August 25, 2016

The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community. Some researchers maintain that environmental ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.